{"entity":{"id":"humanigen","kind":"company","name":"Humanigen","aka":["KaloBios Pharmaceuticals","Humanigen, Inc.","NASDAQ:HGEN"],"tldr":"Humanigen, formerly KaloBios, made lenzilumab, an antibody that neutralises GM-CSF to blunt the cytokine storms of CAR-T therapy and COVID-19, before filing for bankruptcy in 2024.","summary":"Humanigen developed lenzilumab (KB003), a humanised antibody against granulocyte-macrophage colony-stimulating factor. It was studied to prevent cytokine release syndrome and neurotoxicity in patients receiving axicabtagene ciloleucel for lymphoma, in chronic myelomonocytic leukaemia, and in a large randomised trial in hospitalised COVID-19 patients, where the FDA declined emergency authorisation. The company, once KaloBios Pharmaceuticals, filed for Chapter 11 bankruptcy in January 2024.","asOf":"2026-09-17","links":[],"tags":["drug-maker"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["lenzilumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo drug-maker linking round (corporate websites and regulatory records)","editedOn":"2026-09-17"},"hq":"Short Hills, New Jersey","country":"US","companyType":"biotech","stage":"defunct","investors":[],"funding":[]},"route":"/companies/humanigen/","neighbours":{"drug":[{"id":"lenzilumab","kind":"drug","name":"Lenzilumab","route":"/drugs/lenzilumab/"}]}}